TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise against tough breast cancer
Disease control CompletedThis phase 2 trial tested whether adding carboplatin and/or bevacizumab to standard chemotherapy before surgery helps shrink tumors in people with a hard-to-treat type of breast cancer (hormone receptor-poor, HER2-negative, including triple-negative). 454 participants received we…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Breast cancer study: does adding trastuzumab to Pre-Surgery chemo improve outcomes?
Disease control CompletedThis phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail shows promise in tough breast cancer
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for aggressive breast cancer
Disease control CompletedThis study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to 24 people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and red…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise in shrinking aggressive breast tumors before surgery
Disease control CompletedThis study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (atezolizumab) given before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. The trial involved 37…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for tough breast cancer: drug cocktail targets resistant tumors
Disease control CompletedThis phase II trial tested a combination of panitumumab (a targeted therapy) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery to women with triple-negative breast cancer that didn't respond to standard chemo. The goal was to shrink tumors and reduce t…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC